TRI Heart LLC

Lead: Hobey Tam Advisor: Narendra Vyavahare, Ph.D.

300,000+ heart valve replacements annually.

$1.25 BIL market space.

7% CAGR in US. 11 15% CAGR in emerging markets.

Market Dynamics

Our Value Proposition

Glutaraldehyde valves (80% Market Share) Calcification + Structural degradation

Mechanical valves (20% Market Share)

Anticoagulation medication

We have provisionally patented a biomaterial fabrication method for use in heart valve replacements.

TRI valves

Resistant to calcification + structural degradation No anticoagulants req.

The Business Model and Commercialization Strategy.

Not feasible to start and grow enterprise selling heart valves (FDA/CE, established competitors).

TRI Heart, LLC functions to derisk the novel fabrication protocol, TRI.
Core Strategy 50/50 split between R&D and business channel development. Act as pipeline company like in pharma Core values Stay small, agile remain pivotal to have unparalleled pace of bootstrap R&D Exit Strategy Acquisition by a large producer of biomaterials or valves ($30 50MIL)

If it was too much science and numbers

Market Opportunity 300k+ heart valve replacements each year $1.25B market with high growth.

Technology/Product Patented, novel fabrication method for heart valve replacements.

Value Proposition Substantial increase in implant life Enable buyers to grab up market share in valve space Core functions Derisk technology and develop business channels for buyout with angel investor backing. Prelim data for CE/FDA to smoothly transition to clinicals demonstrate safety and efficacy using CE/FDA standards and buyer feedback. TEAM small, agile, and focused Experience + new blood + entrepreneurial focus + incubator/academia

TRI Heart LLC

Trying harder to give you the solutions of tomorrow, today.